Literature DB >> 15699290

Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses.

Carol L M Caton1, Robert E Drake, Deborah S Hasin, Boanerges Dominguez, Patrick E Shrout, Sharon Samet, Bella Schanzer, W Bella Schanzer.   

Abstract

CONTEXT: The distinction between a substance-induced psychosis and a primary psychotic disorder that co-occurs with the use of alcohol or other drugs is critical for understanding illness course and planning appropriate treatment, yet there has been little study and evaluation of the differences between these 2 diagnostic groups.
OBJECTIVE: To identify key demographic, family, and clinical differences in substance-induced psychosis and primary psychotic disorders diagnosed according to DSM-IV criteria using a research diagnostic instrument for psychiatric and substance use comorbidity.
DESIGN: Data on demographic, family, and clinical factors were gathered at baseline as part of a 3-year longitudinal study of early-phase psychosis and substance use comorbidity in New York, NY.
SETTING: Psychiatric emergency department admissions. PARTICIPANTS: The study is based on a referred sample of 400 subjects interviewed at baseline. Participants had at least 1 psychotic symptom assessed during administration of the research protocol, had used alcohol and/or other drugs within the past 30 days, and had no psychiatric inpatient history before the past 6 months. Subject race included 43.5% black, 42.0% Hispanic, and 14.5% white or other. MAIN OUTCOME MEASURE: Psychotic disorders defined by the DSM-IV.
RESULTS: Overall, 169 (44%) were diagnosed as having substance-induced psychosis and 217 (56%), as having primary psychosis. Significant differences were observed in all 3 domains. Multivariate analysis using logistic regression identified the following 3 key predictors as being greater in the substance-induced group: parental substance abuse (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.00-2.85), a diagnosis of dependence on any drug (OR, 9.41; 95% CI, 5.26-16.85), and visual hallucinations (OR, 2.13; 95% CI, 1.10-4.13). The key predictor of total positive and negative symptom score was greater in the primary psychosis group (OR, 0.96; 95% CI, 0.94-0.97).
CONCLUSIONS: Differences in demographic, family, and clinical domains confirm substance-induced and primary psychotic disorders as distinct entities. Key predictors could help emergency clinicians to correctly classify early-phase psychotic disorders that co-occur with substance use.

Entities:  

Mesh:

Year:  2005        PMID: 15699290     DOI: 10.1001/archpsyc.62.2.137

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  29 in total

1.  Gender differences in psychotic disorders with concurrent substance use.

Authors:  Carol L M Caton; Haiyi Xie; Robert E Drake; Gregory McHugo
Journal:  J Dual Diagn       Date:  2014

Review 2.  Enhancing validity in co-occurring disorders treatment research.

Authors:  Gregory J McHugo; Robert E Drake; Mary F Brunette; Haiyi Xie; Susan M Essock; Alan I Green
Journal:  Schizophr Bull       Date:  2006-07-18       Impact factor: 9.306

3.  Prevalence of alcohol-induced psychotic disorders.

Authors:  Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-26       Impact factor: 5.270

4.  Predictors of psychosis remission in psychotic disorders that co-occur with substance use.

Authors:  Carol L M Caton; Deborah S Hasin; Patrick E Shrout; Robert E Drake; Boanerges Dominguez; Sharon Samet; Bella Schanzer
Journal:  Schizophr Bull       Date:  2006-07-27       Impact factor: 9.306

5.  A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis.

Authors:  Robert E Drake; Carol L M Caton; Haiyi Xie; Eustace Hsu; Prakash Gorroochurn; Sharon Samet; Deborah S Hasin
Journal:  Am J Psychiatry       Date:  2011-03-31       Impact factor: 18.112

6.  Psychiatric correlates of injection risk behavior among young people who inject drugs.

Authors:  Mary Ellen Mackesy-Amiti; Geri R Donenberg; Lawrence J Ouellet
Journal:  Psychol Addict Behav       Date:  2014-08-18

Review 7.  Methamphetamine psychosis: epidemiology and management.

Authors:  Suzette Glasner-Edwards; Larissa J Mooney
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

8.  Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).

Authors:  Icro Maremmani; Pier Paolo Pani; Matteo Pacini; Jacopo V Bizzarri; Emanuela Trogu; Angelo Gi Maremmani; Gilberto Gerra; Giulio Perugi; Liliana Dell'Osso
Journal:  Ann Gen Psychiatry       Date:  2010-04-13       Impact factor: 3.455

9.  Prescription opioid misuse and mental health among young injection drug users.

Authors:  Mary E Mackesy-Amiti; Geri R Donenberg; Lawrence J Ouellet
Journal:  Am J Drug Alcohol Abuse       Date:  2014-08-08       Impact factor: 3.829

Review 10.  DSM-V research agenda: substance abuse/psychosis comorbidity.

Authors:  Bruce J Rounsaville
Journal:  Schizophr Bull       Date:  2007-06-07       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.